A naukri.com initiative
Bioengineer
1w
128
Image Credit: Bioengineer
Researchers Identify Promising Target for Fast-Acting Antidepressants with Minimal Side Effects
- Researchers at Tokyo University of Science have discovered that delta opioid receptor (DOP) agonists have potential as fast-acting antidepressants with fewer side effects than traditional medications.
- The study primarily focused on KNT-127, a DOP agonist that has exhibited efficacy in animal models exhibiting symptoms of depression.
- The antidepressant effects of KNT-127 were scrutinized through behavioral and molecular experiments and found to positively impact mice through modulation of the mTOR and PI3K pathways.
- Researchers also discovered that KNT-127 increases glutamatergic transmission by repressing the release of GABA, a neurotransmitter that dampens neuronal excitability.
- The results offer valuable treatment alternatives, particularly for patients resistant to conventional antidepressant therapies.
- It highlights how DOP agonists might directly influence mood regulation mechanisms through specific interactions at the cellular level.
- Scientists deepen understanding of the mechanisms of action- in animal models - a future where fast-acting, safer antidepressants are a reality is closer than ever.
- Animal models exhibited reduced immobility and suggested a robust antidepressant-like effect induced by DOP stimulation.
- These findings add a layer of depth to our understanding of how depression can be addressed at a cellular level.
- DOP agonists like KNT-127 could fundamentally change how we approach the treatment of depression and anxiety disorders.
Read Full Article
7 Likes
For uninterrupted reading, download the app